Lv22
150 积分 2021-12-30 加入
IgA Nephropathy
8小时前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
12天前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
12天前
已完结
POS0230 DISAGREEMENT BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OVER TIME IN PSORIATIC ARTHRITIS: INSIGHT INTO TREATMENT PRIORITIES
12天前
已完结
Efficacy and Safety of Ofatumumab Treatment for Anti‐NMDA Receptor Autoimmune Encephalitis (OFF‐AE): A Prospective, Multicenter Cohort Study
1个月前
已完结
Efficacy and Safety of Ofatumumab Treatment for Anti‐NMDA Receptor Autoimmune Encephalitis (OFF‐AE): A Prospective, Multicenter Cohort Study
1个月前
已完结
Current and emerging therapies for autoimmune encephalitis
1个月前
已完结
Complement and cytokine based therapeutic strategies in myasthenia gravis
4个月前
已完结
B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling
4个月前
已完结
The emerging role of BLyS/APRIL in autoimmune diseases: Biological characteristics, functions, and therapeutic potential
4个月前
已完结
皖公网安备34019202002308
